BioLineRx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

BioLineRx şirketinin toplam hissedar öz sermayesi $8.5M ve toplam borcu $27.8M olup, bu da borç-öz sermaye oranını 326.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $52.7M ve $44.2M dir.

Anahtar bilgiler

326.9%

Borç/özkaynak oranı

US$27.80m

Borç

Faiz karşılama oranı	n/a
Nakit	US$29.17m
Eşitlik	US$8.51m
Toplam yükümlülükler	US$44.24m
Toplam varlıklar	US$52.74m

Son finansal sağlık güncellemeleri

Recent updates

BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer

Jun 29

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

Jun 30

biolinerx EPS beats by $0.17

May 26

BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma

May 04

BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer

Dec 16

biolinerx EPS beats by $0.32

Nov 23

BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress

Nov 18

BioLineRx launches mid-stage combo study in first-line pancreatic cancer

Oct 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BLRX 'nin kısa vadeli varlıkları ( $37.8M ) kısa vadeli yükümlülüklerini ( $25.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: BLRX şirketinin kısa vadeli varlıkları ( $37.8M ) uzun vadeli yükümlülüklerini ( $19.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BLRX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BLRX şirketinin borç/öz sermaye oranı son 5 yılda 23.4% seviyesinden 326.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BLRX son raporlanan serbest nakit akışına göre 12 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: BLRX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/20 20:58
Gün Sonu Hisse Fiyatı	2025/01/17 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

BioLineRx Ltd. 7 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Joseph Pantginis	H.C. Wainwright & Co.
Michael King	JMP Securities
Justin Walsh	JonesTrading Institutional Services, LLC

BioLineRx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Recent updates

BioLineRx Ltd. has filed a Follow-on Equity Offering in the amount of $10 million.

BioLineRx Ltd. has filed a Follow-on Equity Offering in the amount of $8.998765 million.

BioLineRx Ltd. to Report Q3, 2024 Results on Nov 25, 2024

Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024

BioLineRx Ltd. Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

BioLineRx Ltd. announced that it has received $14.6 million in funding

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx stock slips on $15M securities offering

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx files for FDA approval of motixafortide in stem cell mobilization

biolinerx GAAP EPS of -$0.01 beats by $0.08

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

biolinerx EPS beats by $0.17

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer

biolinerx EPS beats by $0.32

BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020

BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections

BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

BioLineRx launches mid-stage combo study in first-line pancreatic cancer

BioLineRx Ltd. has completed a Follow-on Equity Offering.

BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları